Acute heart failure with improved ejection fraction in middle-aged patient with myocarditis and COVID-19 infection.

Małgorzata Tomaszewska; Patrycja Rzesoś; Magdalena Dudek; Magdalena Janus; Ewa Straburzyńska-Migaj

doi:10.20883/medical.e1180

Authors

Małgorzata Tomaszewska Cardiology Department, University Clinical Hospital in Poznan, Poznań, Poland https://orcid.org/0009-0006-7343-1401
Patrycja Rzesoś Cardiology Department, University Clinical Hospital in Poznan, Poznań, Poland https://orcid.org/0009-0009-3949-1760
Magdalena Dudek Cardiology Department, University Clinical Hospital in Poznan, Poznań, Poland https://orcid.org/0000-0001-6550-6182
Magdalena Janus Cardiology Department, University Clinical Hospital in Poznan, Poznań, Poland; 1st Department of Cardiology, Poznan University of Medical Sciences, Poznań, Poland
Ewa Straburzyńska-Migaj Cardiology Department, University Clinical Hospital in Poznan, Poznań, Poland; 1st Department of Cardiology, Poznan University of Medical Sciences, Poznań, Poland https://orcid.org/0000-0002-0545-3370

DOI:

https://doi.org/10.20883/medical.e1180

Keywords:

heart failure, myocarditis, COVID-19

Abstract

This clinical image describes the management of a 48-year-old male with a history of asthma, anxiety-depressive disorder, and prior COVID-19 infection, who was diagnosed with NYHA Class IV heart failure with reduced ejection fraction due to myocarditis.

The patient received an intensive heart failure treatment regimen, including ramipril, eplerenone, bisoprolol, dapagliflozin, ivabradine, and loop diuretics, resulting in a notable clinical improvement and a subsequent reduction in NT-proBNP levels. Upon follow-up, the initiation of sacubitril/valsartan over four months further enhanced functional capacity, leading to an increase in left ventricular ejection fraction to 41% and a decrease in NT-proBNP to 315 pg/ml. Due to these substantial improvements, the need for implantable cardioverter-defibrillator implantation was deemed unnecessary. This case underscores the necessity for early and intensive management of acute heart failure in patients with reduced ejection fraction to facilitate significant recovery. It highlights the rising incidence of myocarditis-related heart failure and emphasizes the need for further investigations to optimize therapeutic strategies for patients with restored left ventricular function.

Downloads

References

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJ, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJ, Mebazaa A, Mindham R, Muneretto C, Piepoli MF, Price S, Rosano GMC, Ruschitzka F, Skibelund AK; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Dec 21;42(48): 4901. Doi: 10.1093/eurheartj/ehab368. PMID: 34447992.

Kasprzak JD, Gorczyca-Głowacka I, Sobczak-Kaleta M, Barylski M, Drożdż J, Filipiak KJ, Kapłon-Cieślicka A, Lelonek M, Mamcarz A, Ochijewicz D, Ryś-Czaporowska A, Starzyk K, Szymański FM, Wełnicki M, Wożakowska-Kapłon B. Pharmacotherapy of heart failure A.D. 2023. Expert opinion of Working Group on Cardiovascular Pharmacotherapy, Polish Cardiac Society. Kardiol Pol. 2023; 81: 537-556. DOI: 10.33963/KP.a2023.0110. PMID: 37179465.

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022; 145: e895–e1032. DOI: 10.1161/CIR.0000000000001063. PMID: 35363499.

Sawalha K, Abozenah M, Kadado AJ, Battisha A, Al-Akchar M, Salerno C, Hernandez-Montfort J, Islam AM. Systematic Review of COVID-19 Related Myocarditis: Insights on Management and Outcome. Cardiovasc Revasc Med. 2021; 23: 107-113. DOI: 0.1016/j.carrev.2020.08.028. PMID: 32847728; PMCID: PMC7434380.

Sai Santhosha Mrudula A, Agarwal P, Vempati R, Alla D, Balusu K, Tarannum S, Patel K, Devaragudi S, Patel D, Sultana Q, Paudel K. Clinical outcome of established diagnostic and treatment modalities of COVID-19-associated myocarditis: a systematic review. Ann Med Surg (Lond). 2023; 85(7): 3583-3594. doi: 10.1097/MS9.0000000000000964. PMID: 37427189.

Castiello T, Georgiopoulos G, Finocchiaro G, Claudia M, Gianatti A, Delialis D, Aimo A, Prasad S. COVID-19 and myocarditis: a systematic review and overview of current challenges. Heart Fail Rev. 2022; 27: 251-261. DOI: 10.1007/s10741-021-10087-9. PMID: 33761041.

Semenzato L, Le Vu S, Botton J, Bertrand M, Jabagi M, Drouin J, Cuenot F, Zores F, Dray-Spira R, Weill A, Zureik M. Long-Term Prognosis of Patients With Myocarditis Attributed to COVID-19 mRNA Vaccination, SARS-CoV-2 Infection, or Conventional Etiologies. JAMA. 2024; 332(16): 1367–77. DOI: 10.1001/jama.2024.16380. PMID: 39186694

Bielecka-Dabrowa A, Cichocka-Radwan A, Lewek J, Pawliczak F, Maciejewski M. Banach M. Cardiac manifestations of COVID-19. Rev Cardiovasc Med. 2021; 22: 365-371. DOI: 10.31083/j.rcm2202043. PMID: 34258904.